Evidence map›Paper›PMID 35804993›Full record

ArticleCancers2022

New Insights into the Multivariate Analysis of SER Spectra Collected on Blood Samples for Prostate Cancer Detection: Towards a Better Understanding of the Role Played by Different Biomolecules on Cancer Screening: A Preliminary Study.

Vlad Cristian Munteanu, Raluca Andrada Munteanu, Diana Gulei, Radu Mărginean, Vlad Horia Schițcu, Anca Onaciu, Valentin Toma, Gabriela Fabiola Știufiuc, Ioan Coman, Rareș Ionuț Știufiuc

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vlad Cristian MunteanuDepartment of Urology, The Oncology Institute "Prof Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
Raluca Andrada Munteanu"Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.ORCID 0000-0003-0617-2084
Diana GuleiMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.ORCID 0000-0002-3030-8626
Radu MărgineanMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.
Vlad Horia SchițcuDepartment of Urology, The Oncology Institute "Prof Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
Anca Onaciu"Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Valentin TomaMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.
Gabriela Fabiola ȘtiufiucFaculty of Physics, "Babes Bolyai" University, 400084 Cluj-Napoca, Romania.
Ioan ComanDepartment of Urology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Rareș Ionuț ȘtiufiucMedFuture-Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania.ORCID 0000-0001-6769-1545

Funding

Iuliu Hațieganu University of Medicine and Pharmacy PCD1530/43Iuliu Hațieganu University of Medicine and Pharmacy PCD 2461/48Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii 40PFE/30.12.2021Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PCE 185/18.02.2021Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P4-ID-PCCF-2016-0112Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P4-ID-PCE-2020-1957
6 · The paper itself

Abstract

It is possible to obtain diagnostically relevant data on the changes in biochemical elements brought on by cancer via the use of multivariate analysis of vibrational spectra recorded on biological fluids. Prostate cancer and control groups included in this research generated almost similar SERS spectra, which means that the values of peak intensities present in SERS spectra can only give unspecific and limited information for distinguishing between the two groups. Our diagnostic algorithm for prostate cancer (PCa) differentiation was built using principal component analysis and linear discriminant analysis (PCA-LDA) analysis of spectral data, which has been widely used in spectral data management in many studies and has shown promising results so far. In order to fully utilize the entire SERS spectrum and automatically determine the most meaningful spectral features that can be used to differentiate PCa from healthy patients, we perform a multivariate analysis on both the entire and specific spectral intervals. Using the PCA-LDA model, the prostate cancer and control groups are clearly distinguished in our investigation. The separability of the following two data sets is also evaluated using two alternative discrimination techniques: principal least squares discriminant analysis (PLS-DA) and principal component analysis-support vector machine (PCA-SVM).

Indexed as

multivariate analysisprostate cancerRamanSERS

Identifiers

PMID35804993
PMCPMC9264810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.